Definitive Contract HHSN261201500021C
Award Date 9/18/15
Potential Completion Date 11/19/18
Potential Value $992K
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Atlanta, GA 30303, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed Similar Awards
- <p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Omicron Biochemicals, Inc. The $999,991.00 fixed-price contract is for the "Synthesis of High-Mannose N-Glycans" and was awarded on September 18, 2015, with a completion date of September 17, 2017. The contract is a definitive contract, indicating it is a stand-alone award rather than under a larger contract vehicle.</p>
- <p>This is a $999,898 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Glycobia Inc., a small business, under the SBIR Phase II program. The contract is for the development of chemically defined glycan libraries for use as reference standards and in glycomics research, under a joint NCI-NIGMS program. The contract has a small business set aside designation and runs through September 2018.</p>
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Glycohub, Inc., a woman-owned small business. The contract is for the delivery of chemically defined glycosphingolipid head groups, with a total ceiling value of $298,447.00 and a completion date of December 30, 2014. As an SBIR Phase I contract, this represents the initial research and development effort to explore the feasibility of the proposed technology....
- <p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Biotex, Inc. The contract is for the development of glycosylation-specific research, with a ceiling value of $149,919.00 and a completion date of October 14, 2012. The contract is a definitive contract with a firm fixed-price pricing type. This SBIR Phase I action is a set-aside for small businesses.</p>
- This is a $1,646,541.00 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS), to Glycan Therapeutics Corporation, a small disadvantaged business. The contract is for the chemoenzymatic synthesis of heparin sulfate under the Small Business Innovation Research (SBIR) Phase II program. The work is focused on developing synthetic heparan sulfate...
- This is a Phase II Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Siamab Therapeutics, Inc. The purpose of the contract is to develop technologies to characterize glycan moieties of glycoproteins in order to enhance the diagnostic capability of protein-based biomarkers. The specific goals include expanding the number of features for an existing sialic acid glycan array, optimizing the serum assay protocol,...
- This is a Small Business Innovation Research (SBIR) contract awarded by the National Institutes of Health's (NIH) National Cancer Institute (NCI) to Glycoscientific, L.L.C., a small business research company. The contract is for the development of glycosylation-specific research reagents, including antibodies and aptamers, under SBIR Topic 294 Phase I. The contract has a ceiling value of $149,951 and was awarded on a firm fixed-price basis. This contract was set aside for total small business...
- The U.S. National Cancer Institute awarded a $299,447 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract to Glycan Therapeutics Corporation, a small disadvantaged business, to conduct research on the chemoenzymatic synthesis of heparin sulfate oligosaccharides. Glycan Therapeutics specializes in developing methods for synthesizing and analyzing sulfated carbohydrates like heparan sulfate, which have potential therapeutic applications. This contract supports Glycan...
- <p>The U.S. National Cancer Institute awarded a $1,300,000.00 Small Business Innovation Research (SBIR) Program Phase I contract to Cassia, LLC for the "ENZYMATIC SYNTHESIS OF GLYCANS." This is a Firm Fixed Price Definitive Contract with a period of performance through September 30, 2016. The contract is for research and development related to enzymatic synthesis of glycans, which are complex carbohydrate molecules.</p>
- This is a SBIR Program Phase I action contract awarded by the National Cancer Institute, a civilian agency, to 3D Glass Solutions, Inc., a small business manufacturer, for the development of a chemical library of O-glycosyl amino acid building blocks. The contract is a firm fixed price definitive contract with a ceiling value of $299,034.00 and an ultimate completion date of August 13, 2014. This represents the first phase of a Small Business Innovation Research (SBIR) program, where the...